BridgeBio Pharma, Inc. (BBIO) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hear the whistle blowing. I can hear the mighty roar. I can hear the horses prancing in the postures of the lord. Oh, the train is coming, My baby's coming back now on the next train. I can hear the whistle blowing. I can hear the mighty roar. I can hear the horses prancing in the pastures of the lord. Oh, the train is coming, Good afternoon. I will be your conference operator today. All lines have been placed on mute to prevent any background noise. After the company's remarks, there will be a question and answer session. Thank you. Before we begin, I would like to remind everyone that today's call may contain forward looking statements within the meaning of the federal securities laws, including, but not limited to, statements about BridgeBio's future operating and financial performance, business plans and prospects and strategy. These statements are based on current expectations and assumptions that are subject to risks and uncertainties, which could cause actual results to differ materially from those expressed or implied in these forward looking statements. For a discussion of these risks and uncertainties, please refer to the disclosure in today's earnings release and BridgeBio's periodic reports and SEC filings. All statements made here are based on information available to BridgeBio as of today, The company undertakes no obligation to update any forward looking statements made during this call, except as required by law. With that completed, BridgeBio, you may begin your conference. Good afternoon, everyone, and thank you for joining BridgeBio Pharma's first quarter twenty twenty six earnings call. I'm Chunai Shukla, senior vice president, strategic finance. With me are Neil Kumar, our CEO Matt Alton, our chief commercial officer and Tom Trimarkey, our presid...